Connect Biopharma (CNTB)

Executive Summary

Connect Biopharma (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company based in China, dedicated to discovering and developing novel immune modulators for chronic inflammatory diseases with high unmet medical need. The company's lead candidate, rademikibart (CBP-201), is a monoclonal antibody targeting IL-4Rα currently in late-stage clinical trials for atopic dermatitis and asthma. Additionally, CBP-307, a next-generation S1P1 receptor modulator, is being evaluated for ulcerative colitis and Crohn's disease. With operations spanning Greater China, the United States, and Australia, Connect Biopharma leverages its proprietary platforms to advance a pipeline focused on dermatology and gastroenterology. The company's progress is subject to regulatory oversight from the FDA and China's NMPA, positioning it for potential value inflection as it approaches key data readouts and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 topline data for rademikibart in atopic dermatitis70% success
• Q4 2026Phase 2 initiation for CBP-307 in ulcerative colitis80% success
• Q1 2027NMPA submission for rademikibart in atopic dermatitis60% success